CASI Pharmaceuticals Inc (CASI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CASI Pharmaceuticals Inc (CASI) has a cash flow conversion efficiency ratio of -0.014x as of March 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-843.00K) by net assets ($62.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CASI Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1994–2024)
This chart illustrates how CASI Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CASI current and long-term liabilities for a breakdown of total debt and financial obligations.
CASI Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CASI Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vault Strategic Mining Corp.
V:KNOX
|
0.054x |
|
NEX Metals Exploration Ltd
AU:NME
|
0.158x |
|
Nagreeka Capital & Infrastructure Limited
NSE:NAGREEKCAP
|
0.407x |
|
NedSense Enterprises NV
AS:NEDSE
|
-0.002x |
|
Horus AG
STU:HRU
|
N/A |
|
Alliance Pharma plc
LSE:APH
|
0.099x |
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
-0.455x |
|
Yunnan Water Investment Co. Limited
F:2WI
|
-0.010x |
Annual Cash Flow Conversion Efficiency for CASI Pharmaceuticals Inc (1994–2024)
The table below shows the annual cash flow conversion efficiency of CASI Pharmaceuticals Inc from 1994 to 2024. For the full company profile with market capitalisation and key ratios, see CASI stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.85 Million | $-29.22 Million | -15.788x | -1810.76% |
| 2023-12-31 | $24.16 Million | $-19.97 Million | -0.826x | -162.26% |
| 2022-12-31 | $66.93 Million | $-21.09 Million | -0.315x | -26.72% |
| 2021-12-31 | $107.96 Million | $-26.84 Million | -0.249x | +0.52% |
| 2020-12-31 | $103.57 Million | $-25.89 Million | -0.250x | -0.72% |
| 2019-12-31 | $93.67 Million | $-23.24 Million | -0.248x | +4.97% |
| 2018-12-31 | $109.46 Million | $-28.58 Million | -0.261x | -57.19% |
| 2017-12-31 | $38.54 Million | $-6.40 Million | -0.166x | +42.68% |
| 2016-12-31 | $20.78 Million | $-6.02 Million | -0.290x | -132.00% |
| 2015-12-31 | $-6.09 Million | $-5.51 Million | 0.906x | -90.43% |
| 2014-12-31 | $-422.21K | $-4.00 Million | 9.463x | +4416.67% |
| 2013-12-31 | $14.94 Million | $-3.28 Million | -0.219x | +18.39% |
| 2012-12-31 | $8.24 Million | $-2.21 Million | -0.269x | +84.08% |
| 2011-12-31 | $2.53 Million | $-4.27 Million | -1.687x | -81.46% |
| 2010-12-31 | $5.33 Million | $-4.96 Million | -0.930x | -117.54% |
| 2009-12-31 | $-1.93 Million | $-10.21 Million | 5.303x | +251.61% |
| 2008-12-31 | $5.92 Million | $-20.71 Million | -3.498x | -299.91% |
| 2007-12-31 | $26.90 Million | $-23.52 Million | -0.875x | -97.78% |
| 2006-12-31 | $46.98 Million | $-20.77 Million | -0.442x | +10.49% |
| 2005-12-31 | $29.39 Million | $-14.52 Million | -0.494x | -7.57% |
| 2004-12-31 | $35.72 Million | $-16.41 Million | -0.459x | +33.95% |
| 2003-12-31 | $34.88 Million | $-24.25 Million | -0.695x | +83.95% |
| 2002-12-31 | $10.51 Million | $-45.53 Million | -4.332x | -90.19% |
| 2001-12-31 | $23.21 Million | $-52.87 Million | -2.278x | +1.89% |
| 2000-12-31 | $19.06 Million | $-44.25 Million | -2.322x | -42.68% |
| 1999-12-31 | $22.00 Million | $-35.80 Million | -1.627x | -332.20% |
| 1998-12-31 | $33.20 Million | $-12.50 Million | -0.377x | -140.17% |
| 1997-12-31 | $42.10 Million | $-6.60 Million | -0.157x | -239.90% |
| 1996-12-31 | $47.70 Million | $-2.20 Million | -0.046x | +96.26% |
| 1995-12-31 | $3.60 Million | $-4.44 Million | -1.233x | +94.33% |
| 1994-12-31 | $200.00K | $-4.35 Million | -21.750x | -- |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more